PSE (Pseudoephedrine)

Browse PSE (Pseudoephedrine) Content

Submission

The DEA invited comments on the proposed rule to revise existing regulations that manage quotas for controlled substances and List I chemicals held by DEA-registered manufacturers. We have comments on three areas within the proposed rule.

Dec 23, 2019

Press Releases and Statements

CHPA applauds New Hampshire for becoming the 35th state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx), a system used by retailers across the country to help prevent the illegal sale of pseudoephedrine.

Jun 7, 2018

Press Releases and Statements

CHPA applauds the state of Georgia for becoming the thirty-third state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx).

Apr 28, 2016

Press Releases and Statements

CHPA highlights the results of a recent five-state survey from the Asthma and Allergy Foundation of America, which found that consumers on the whole, prefer full access to OTC medicine containing pseudoephedrine.

Jul 22, 2015

Article

So far, 31 states have adopted real-time, stop-sale technology. The blocking technology monitors all nonprescription PSE purchases in real-time to prevent meth criminals from exceeding legal limits.

Mar 31, 2014

Submission

Today, the manufacturers of OTC medicines containing pseudoephedrine call on Congress to improve the Combat Methamphetamine Epidemic Act by requiring a unified, national electronic tracking system to block illegal sales of PSE‐containing medicines.

Apr 13, 2010

Submission

Letter from the Consumer Healthcare Products Association, the Food Marketing Institute, the Healthcare Distribution Management Association, and the National Association of Chain Drugstores regarding controlled substances and Lis I chemical registration application fees.

Jan 17, 2006

Submission

CHPA is deeply concerned that safe and effective medicines manufactured by its member companies are being diverted to manufacture meth. We understand the scope of this problem and are committed to the need for strong action to prevent the diversion of these important medicines to the illegal manufacturing of methamphetamine.

Oct 20, 2005

Submission

We submit these comments on behalf of CHPA in response to the proposed rule regarding security requirements for manufacturers, distributors, importers, and exporters of pseudoephedrine, ephedrine, and phenylpropanolamine.

Oct 28, 2004

Submission

This letter is submitted on behalf of CHPA, FMI, HDMA, and NACDS. The purpose of the letter is to express our united concern that the DEA’s proposed rule is not supported by existing evidence and will impose a significant burden on the regulated industry.

Oct 22, 2004

Filter Results